Litcius/Paper detail

Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study

Rachel Ochs-Ross, Ewa Wajs, Ella Daly, Yun Zhang, Rosanne Lane, Pilar Lim, Wayne C. Drevets, David C. Steffens, Gerard Sanacora, Carol Jamieson, David Hough, Husseini K. Manji, Jaskaran Singh

2021American Journal of Geriatric Psychiatry43 citationsDOIOpen Access PDF

Topics & Concepts

TolerabilityMedicineAdverse effectDepression (economics)Internal medicinePost-hoc analysisAntidepressantTreatment-resistant depressionEconomicsMacroeconomicsHippocampusTreatment of Major DepressionDigital Mental Health InterventionsAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study | Litcius